Strategically designed to foster an understanding of both the disease state complexity and far-reaching disparity intrinsic to endometrial cancer, this educational session will begin with an appraisal of the utility and importance of biomarker testing in advanced endometrial cancer, and the latest data related to immune checkpoint inhibitor treatments.